Eric Dube, Ph.D., is the president and chief executive officer of Travere Therapeutics and serves as a member of the company’s board of directors. He is a results-driven leader who is committed to patients and integrating their perspective into all aspects of the company’s operations. At Travere Therapeutics, Dr. Dube oversees a global team dedicated to identifying, developing and delivering life-changing therapies to people living with rare disease, as well as the advancement of the company’s promising pipeline featuring an innovative product candidate with first-in-class potential. With leadership experience across the United States, Europe and Japan, Dr. Dube draws upon significant expertise in managing commercial, operations, market access, medical and business development functions.
Prior to joining Travere Therapeutics, Dr. Dube was president and head of North America at ViiV Healthcare, where he led the commercialization of pipeline assets and oversaw the governance of all pricing, strategy, policy and investment decisions for the company’s North America business. Before joining ViiV, for more than 18 years he worked in roles of increasing leadership at GlaxoSmithKline plc, spanning critical areas, including sales, marketing, market access, medical affairs, compliance, supply chain and alliance management. During Dr. Dube’s tenure at GSK, he also led the US Oncology and Global Respiratory businesses. He currently serves on the board of trustees for AIDS United, the executive committee of the board of directors for the Biotechnology Innovation Organization (BIO), and the board of directors for Biocom California and Reneo Pharmaceuticals.
Dr. Dube has been recognized by PharmaVOICE magazine as one of the “100 Most Inspiring People” in the life sciences industry, the Financial Times as one of the “OUTstanding 100 LGBT+ Executives, and Pharmaceutical Executive as one of the “Emerging Pharma Leaders”. Earlier in his career, Fortune magazine named him a “40 Under 40: Ones to Watch”.
Dr. Dube graduated from Santa Clara University with a B.S. in biopsychology and earned an M.A. and Ph.D. in psychology from Cornell University, where his studies focused on how culture, gender and ethnicity influenced resilience in the LGBTQ community.
What is Eric M. Dube's net worth?
The estimated net worth of Eric M. Dube is at least $6.22 million as of September 9th, 2024. Dr. Dube owns 361,975 shares of Travere Therapeutics stock worth more than $6,218,731 as of December 22nd. This net worth estimate does not reflect any other investments that Dr. Dube may own. Additionally, Dr. Dube receives an annual salary of $1,400,000.00 as CEO at Travere Therapeutics. Learn More about Eric M. Dube's net worth.
What is Eric M. Dube's salary?
How do I contact Eric M. Dube?
Has Eric M. Dube been buying or selling shares of Travere Therapeutics?
Eric M. Dube has not been actively trading shares of Travere Therapeutics during the last ninety days. Most recently, Eric M. Dube sold 21,125 shares of the business's stock in a transaction on Monday, September 9th. The shares were sold at an average price of $11.52, for a transaction totalling $243,360.00. Following the completion of the sale, the chief executive officer now directly owns 361,975 shares of the company's stock, valued at $4,169,952. Learn More on Eric M. Dube's trading history.
Who are Travere Therapeutics' active insiders?
Are insiders buying or selling shares of Travere Therapeutics?
During the last year, insiders at the sold shares 20 times. They sold a total of 172,896 shares worth more than $2,164,946.05. The most recent insider tranaction occured on November, 25th when CAO Sandra Calvin sold 12,090 shares worth more than $221,247.00. Insiders at Travere Therapeutics own 3.8% of the company.
Learn More about insider trades at Travere Therapeutics. Information on this page was last updated on 11/25/2024.
